In order to create novel and better therapies for the treatment of T-cell lymphoma, market participants are concentrating on thorough research in the field of this disease. Obtaining regulatory approvals for their T-cell lymphoma treatment solutions is a focus of manufacturers in the global T-cell lymphoma market. For instance, in May 2020, China's National Medical Products Administration (NMPA) approved the use of the pharmaceutical company Takeda Pharmaceutical Company Limited's injection ADCETRIS (brentuximab vedotin), which is indicated for the treatment of patients with systemic anaplastic large cell lymphoma that has relapsed or is resistant to treatment (a type of T-cell lymphoma).
The global T-Cell Lymphoma Market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to exhibit a CAGR of 9.8% over the forecast period (2021-2028).
Prominent Players in the T-Cell Lymphoma Industry:
1. F. Hoffmann-La Roche Ltd.
Roche Holding AG engages in the pharmaceuticals and diagnostics. The company was founded in 1896 and is headquartered in Basel, Switzerland.
2. Biocryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. In January, 2023 Biocryst Pharmaceuticals Inc. announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO® (berotralstat) in Central and Eastern Europe (CEE).
3. Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products globally from 1887. The company was headquartered in New York, New York. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
4. Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. The company was incorporated in 1949 and is headquartered in Tokyo, Japan.
5. Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
6. GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. On May 2020, it was reported that GSK tap experimental arthritis antibody to calm cytokine storm hitting COVID-19 patients.
7. Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. On October 2022, The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer.
8. Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. In January, 2023 Merck completes acquisition of the chemical business of Mecaro.
9. Novartis AG.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Novartis in December, 2022 announced the European Commission (EC) approved Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy
10. Bausch Health Companies Inc
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It was founded in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada. On Aug. 10, 2022 Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced its support of the publication of a new specific ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE) based on the growing incidence of chronic liver disease in the United States.
*Definition- T-cell lymphoma is a form of blood cancer that develops from uncontrolled growth and multiplication of T-cell lymphocytes found in the human immune system.
